## **Core Concept**
The question tests knowledge of fibrinolytic agents, specifically their antigenic properties. Fibrinolytic agents are used to dissolve blood clots and are crucial in managing conditions like acute ischemic stroke, pulmonary embolism, and myocardial infarction. Some of these agents can induce an immune response, making them antigenic.

## **Why the Correct Answer is Right**
Streptokinase (SK) is a fibrinolytic agent derived from certain strains of streptococci. It works by forming a complex with plasminogen, which then converts other plasminogen molecules to plasmin, leading to clot dissolution. Due to its bacterial origin, streptokinase can trigger an immune response in patients, making it antigenic. This property can limit its use in patients who have been previously exposed to streptococcal infections or have received streptokinase before, as it may reduce its efficacy.

## **Why Each Wrong Option is Incorrect**
- **Option A:** Alteplase is a recombinant tissue plasminogen activator (rt-PA) used for fibrinolysis. It is not derived from bacterial sources and is less likely to cause an immune response compared to streptokinase. Therefore, it is not typically considered antigenic.
- **Option B:** Urokinase is another fibrinolytic agent but it is not known for being antigenic like streptokinase.
- **Option C:** Tenecteplase is a variant of alteplase with mutations that make it more fibrin-specific and longer-acting. Like alteplase, it is not known for significant antigenicity.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that streptokinase's antigenic potential can lead to the formation of antibodies against it, which might necessitate the use of alternative fibrinolytic agents in certain clinical scenarios. This is particularly relevant in patients with a history of recent streptococcal infection or previous exposure to streptokinase.

## **Correct Answer:** . Streptokinase